Ulas Turgay, Buyukhatipoglu Hakan, Dal Mehmet S, Kirhan Idris, Kaya Zekeriya, Demir Mehmet E, Tursun Irfan, Eren Mehmet A, Aydogan Timucin, Sezen Yusuf, Aksoy Nurten
Department of Internal Medicine, Harran University, Faculty of Medicine, Sanliurfa, Turkey.
J Res Med Sci. 2013 Mar;18(3):205-9.
Contrast induced kidney injury is an acute renal dysfunction that is secondary to the administration of radio contrast media. The purpose of this study was to evaluate the levels of urotensin-II (UT-II) and endothelin-I (ET-I) after contrast media administration in patients undergoing percutaneous coronary interventions.
In this prospective cohort study, we evaluated 78 patients with coronary artery disease who were scheduled for and ultimately underwent percutaneous coronary interventions. As a contrast material, nonionic contrast media was used in various amounts (70-480 mL). Blood and urine samples were obtained to measure U-II, ET-I just before and at the twenty-fourth hour of percutaneous coronary interventions.
Compared to baseline, twenty-fourth hour creatinine levels were significantly increased (P < 0.001). The twenty-fourth hour serum and urine levels of both UT-II and ET-I were also significantly increased compared to baseline (P < 0.001 for all) and 24(th) hour serum and urine UT-II (r = 0.322, P = 0.004; r = 0.302, P = 0.007 respectively), ET-I (r = 0.511, P < 0.001; r = 0.266, P = 0.019 respectively) levels were significantly correlated with the amount of contrast media.
Our study indicates that; increased UT-II and ET-I levels seem to be a consequence of hazardous effects of contrast media on blood vessels and the kidney.
对比剂诱导的肾损伤是一种继发于放射性对比剂给药后的急性肾功能障碍。本研究的目的是评估接受经皮冠状动脉介入治疗的患者在使用对比剂后尿紧张素-II(UT-II)和内皮素-I(ET-I)的水平。
在这项前瞻性队列研究中,我们评估了78例计划并最终接受经皮冠状动脉介入治疗的冠心病患者。作为对比剂,使用了不同剂量(70 - 480 mL)的非离子型对比剂。在经皮冠状动脉介入治疗前及治疗后第24小时采集血液和尿液样本,以测量UT-II、ET-I。
与基线相比,第24小时的肌酐水平显著升高(P < 0.001)。与基线相比,第24小时UT-II和ET-I的血清及尿液水平也显著升高(均P < 0.001),且第24小时血清和尿液中的UT-II(分别为r = 0.322,P = 0.004;r = 0.302,P = 0.007)、ET-I(分别为r = 0.511,P < 0.001;r = 0.266,P = 0.019)水平与对比剂用量显著相关。
我们的研究表明,UT-II和ET-I水平升高似乎是对比剂对血管和肾脏产生有害影响的结果。